Considering investing in biotech stocks? While the best biotech stocks depend on your portfolio and investment goals, we've identified some biotech stocks that are worth keeping an eye on in the healthcare sector. Keep reading to learn more about biotech stocks and how to start investing.
We round up a selection of stocks in or related to the healthcare industry, weighting the list more heavily towards popular mid- and large-cap stocks.
| Best stock | 1-year return | Market cap | Exchange | Volume | Buy on Questrade |
|---|---|---|---|---|---|
| Amgen (AMGN.US) | 26.53% | $182.2 billion (USD) | NASDAQ | 2,494,900 | Buy now |
| Vertex Pharmaceuticals (VRTX.US) | 5.24% | $114.6 billion (USD) | NASDAQ | 1,818,617 | Buy now |
| Novartis AG ADR (NVS.US) | 26.73% | $289.2 billion (USD) | NYSE | 1,380,531 | Buy now |
| Gilead Sciences (GILD.US) | 17.59% | $153.7 billion (USD) | NASDAQ | 7,896,115 | Buy now |
| Intellia Therapeutics (NTLA.US) | 69.77% | $2.3 billion (USD) | NASDAQ | 8,849,200 | Buy now |
| Crispr Therapeutics (CRSP.US) | 18.75% | $5.3 billion (USD) | NASDAQ | 1,941,400 | Buy now |
| Krystal Biotech (KRYS.US) | 149.01% | $10.2 billion (USD) | NASDAQ | 411,614 | Buy now |
| Bio-Techne (TECH.US) | 17.53% | $8.8 billion (USD) | NASDAQ | 3,773,100 | Buy now |
| Helix BioPharma (HBP.TO) | 66.67% | $108.5 million (CAD) | Toronto Stock Exchange | 516 | Buy now |
| Spectral Med (EDT.TO) | 56.32% | $399 million (CAD) | Toronto Stock Exchange | 40,600 | Buy now |
The healthcare industry is affected by a range of complex factors such as trade policies, regulations, and fluctuating supply and demand. So when considering biotech stocks to buy, it's important that you have access to vital information about a company's financial health, leadership team, and market positioning.
Also keep in mind that, while volatility can be ideal for day traders, long-term investors will want to look for stocks to offer steadier gains over time.
A lot of factors go into picking the best biotech stocks. Stock performance can be impacted by factors like market conditions, company decisions and global events. Plus, what may be a strong biotech stock investment for one person might not be suitable for another.
That said, we rounded up this list of popular biotech stocks in or related to the healthcare industry to help narrow down your options:
Keep in mind that this is not a "best" list or a recommendation. It highlights some biotech stocks for informational purposes only and does not indicate past or future performance or investment advice. We do not guarantee any investment performance.
We've outlined detailed company and stock performance details for each biotech stock below. Keep reading to decide if any of these companies are the right investment for you.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI.
| Closing stock price | $344.72 |
|---|---|
| Market Capitalization | $182.2 billion |
| Gross profit (TTM) | $26.6 billion |
| Profit margin | 20.96% |
| Revenue (TTM) | $37.2 billion |
| Earnings per share (TTM) | $14.37 |
| 52-week stock price range | $260.01 – $388.36 |
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor.
| Closing stock price | $466.79 |
|---|---|
| Market Capitalization | $114.6 billion |
| Gross profit (TTM) | $6.6 billion |
| Profit margin | 35.51% |
| Revenue (TTM) | $12.2 billion |
| Earnings per share (TTM) | $16.86 |
| 52-week stock price range | $362.50 – $507.92 |
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD).
It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta.
| Closing stock price | $148.93 |
|---|---|
| Market Capitalization | $289.2 billion |
| Gross profit (TTM) | $42.7 billion |
| Profit margin | 23.92% |
| Revenue (TTM) | $56.6 billion |
| Earnings per share (TTM) | $6.99 |
| 52-week stock price range | $109.02 – $165.43 |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients.
| Closing stock price | $124.87 |
|---|---|
| Market Capitalization | $153.7 billion |
| Gross profit (TTM) | $23.6 billion |
| Profit margin | 30.99% |
| Revenue (TTM) | $29.7 billion |
| Earnings per share (TTM) | $7.35 |
| 52-week stock price range | $101.81 – $155.38 |
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats ("CRISPR")/CRISPR associated 9 ("Cas9") technology for genome editing.
The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases.
| Closing stock price | $15.67 |
|---|---|
| Market Capitalization | $2.3 billion |
| Gross profit (TTM) | $-230,670,000 |
| Revenue (TTM) | $66.1 million |
| Earnings per share (TTM) | -$3.52 |
| 52-week stock price range | $7.95 – $28.25 |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology.
| Closing stock price | $54.09 |
|---|---|
| Market Capitalization | $5.3 billion |
| Gross profit (TTM) | $-478,712,992 |
| Revenue (TTM) | $4.1 million |
| Earnings per share (TTM) | -$6.17 |
| 52-week stock price range | $43.23 – $78.48 |
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.
| Closing stock price | $343.43 |
|---|---|
| Market Capitalization | $10.2 billion |
| Gross profit (TTM) | $393 million |
| Profit margin | 53.93% |
| Revenue (TTM) | $417.3 million |
| Earnings per share (TTM) | $7.48 |
| 52-week stock price range | $130.17 – $347.67 |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
| Closing stock price | $57.94 |
|---|---|
| Market Capitalization | $8.8 billion |
| Gross profit (TTM) | $804 million |
| Profit margin | 9.05% |
| Revenue (TTM) | $1.2 billion |
| Earnings per share (TTM) | $0.70 |
| 52-week stock price range | $43.12 – $71.93 |
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer.
It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor.
| Closing stock price | C$1.50 |
|---|---|
| Market Capitalization | C$108.5 million |
| Earnings per share (TTM) | -C$0.04 |
| 52-week stock price range | C$0.84 – C$5.40 |
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream.
It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.
| Closing stock price | C$1.36 |
|---|---|
| Market Capitalization | C$399 million |
| Gross profit (TTM) | C$1.6 million |
| Revenue (TTM) | C$2.8 million |
| Earnings per share (TTM) | -C$0.13 |
| 52-week stock price range | C$0.77 – C$1.76 |
Compare special offers, low fees and a wide range of investment options among popular trading platforms in Canada. Note that the dollar amounts in the table below are in CAD.
To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score, the better the platform—it's that simple.
Learn how to buy SpaceX stock in Canada and see stock performance history over time.
We break down which companies hold Ethereum, why they’re doing it and what ETH treasuries mean for markets and investors.
Want to invest in the Euro Stoxx 50 in Canada? Explore investment platforms and popular Euro Stoxx 50 index funds.
Want to invest in iGambling companies? We’ve put together a list of online gambling stocks you should keep your eye on.
Want to invest in pipeline companies? We’ve put together a list of pipeline stocks you should keep your eye on.
These are the best renewable energy stocks to buy now in Canada.
Want to invest in financial services companies in Canada? Here’s a list of Canadian bank stocks you should keep your eye on.
Want to invest in consumer staples companies? We’ve put together a list of food stocks you should keep your eye on.
Want to invest in coal companies? We’ve put together a list of coal stocks you should keep your eye on.
Want to invest in automated technology? We’ve put together a list of robotics stocks you should keep your eye on.
Want to invest in cobalt companies? We’ve put together a list of cobalt stocks you should keep your eye on.
Want to invest in energy companies? We’ve put together a list of energy stocks you should keep your eye on.